A Prospective Comparative Interventional Study to Determine the Safety and Efficacy of Intralesional Acyclovir versus Vaccine MMR in the treatment of Viral warts- RANDOMIZED CONTROL TRIAL

This study is a prospective, randomized, comparative interventional trial designed to evaluate and compare the efficacy and safety of intralesional acyclovir versus intralesional MMR vaccine in the treatment of cutaneous viral warts. Viral warts, caused by human papillomavirus (HPV), are common dermatological conditions with variable response to conventional destructive therapies and a tendency for recurrence, prompting the need for effective immunomodulatory or antiviral alternatives

A total of 60 adult patients (>18 years) with clinically diagnosed palmar, plantar, periungual, or subungual warts will be recruited and randomly allocated into two groups. Group A will receive intralesional acyclovir (70 mg/mL), and Group B will receive intralesional MMR vaccine, administered every two weeks for up to six sessions or until complete clearance. Treatment response will be assessed using objective reduction in wart size and number (graded G0–G4), physician global assessment, and patient satisfaction scores, with follow-up for adverse effects and short-term recurrence

The primary objective is to compare therapeutic efficacy between the two modalities, while secondary objectives include evaluation of safety and tolerability.